What is Ozempic?

What Ozempic is - and what it is approved for

Ozempic is the brand name for a once-weekly semaglutide injection made by Novo Nordisk. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. In the United States it is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

That labeled use matters for searchers who hear Ozempic discussed as a weight-loss shot. The manufacturer states that Ozempic is not a weight-loss drug. A related weekly semaglutide product, Wegovy, carries chronic weight-management and certain cardiovascular indications in people with overweight or obesity. Those are different FDA-approved products with different labeled doses and patient populations. A clinician, not a webpage, matches a medicine to a diagnosis.

This article is educational, not medical advice, and it is not an offer to prescribe or dispense Ozempic. Beema Health does not sell branded Ozempic. Ozempic requires a prescription. Completing an online visit anywhere does not guarantee that a licensed provider will prescribe any medication. Individual results vary, and no weight-loss outcome is guaranteed.

How weekly semaglutide acts in type 2 diabetes

GLP-1 receptor agonists mimic a gut hormone that helps the pancreas release insulin when blood glucose is high, reduces glucagon, and slows gastric emptying. Those actions support lower A1C in type 2 diabetes. Many people also notice less hunger, which can lead to weight change, but that is not the approved indication for Ozempic.

Cardiovascular and kidney outcome trials helped expand the label beyond glucose alone. SUSTAIN-6 found that adding semaglutide to standard care reduced major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. The FLOW trial supported a kidney-protection indication in adults with type 2 diabetes and chronic kidney disease. Those studies enrolled defined populations. They do not mean every adult who wants to lose weight is a candidate for Ozempic.

How Ozempic is taken and how doses are increased

Ozempic is injected under the skin once weekly, on the same day each week, with or without food. Injection sites are the abdomen, thigh, or upper arm, rotated to reduce local irritation. If a dose is missed, the prescribing information generally allows administration within five days; after that window, the missed dose is skipped and the regular schedule resumes. A clinician should confirm the missed-dose plan that matches the current label.

Labeled titration starts at 0.25 mg once weekly for four weeks. That starting dose is for gastrointestinal tolerability, not for long-term glycemic control. After four weeks the usual next step is 0.5 mg weekly. If more glycemic control is needed, the dose may increase to 1 mg weekly after at least four weeks on 0.5 mg, and later to 2 mg weekly after at least four weeks on 1 mg. For the chronic kidney disease outcome indication, the label directs increasing to a 1 mg weekly maintenance dose after at least four weeks on 0.5 mg.

Only a licensed prescriber should set the dose. People should not split pens, share devices, or invent a schedule from social media. Ozempic pens must never be shared between patients, even if the needle is changed.

• Weeks 1-4: 0.25 mg once weekly (initiation)
• Then 0.5 mg once weekly
• If needed for glucose control: 1 mg, then up to 2 mg once weekly after at least four weeks at the prior dose
• Kidney-outcome maintenance described on the label: 1 mg once weekly after the 0.5 mg step

Who was studied - and who is not a candidate on the label

Registration and outcome trials enrolled adults with type 2 diabetes, often with additional cardiovascular or kidney disease. Ozempic is not indicated for type 1 diabetes. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with MEN 2, and after a serious hypersensitivity reaction to semaglutide or product excipients.

Clinicians also screen for other labeled warnings: history of pancreatitis, diabetic retinopathy (which should be monitored, especially if glucose falls quickly), severe gastrointestinal disease including severe gastroparesis (Ozempic is not recommended in that setting), gallbladder disease, and pregnancy. Semaglutide has a long half-life. Labels for related products advise discontinuing well before a planned pregnancy; anyone who is pregnant, planning pregnancy, or breastfeeding should talk with their clinician rather than following internet dosing advice.

Pulmonary aspiration during general anesthesia or deep sedation has been reported with GLP-1 receptor agonists. People should tell surgical and anesthesia teams that they use a weekly GLP-1 medicine before elective procedures.

Boxed warning, common effects, and when to get care

Ozempic carries a boxed warning about thyroid C-cell tumors. In rodents, semaglutide caused thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic causes medullary thyroid carcinoma in humans. Patients should be counseled about symptoms of thyroid tumors, such as a neck mass, trouble swallowing, shortness of breath, or persistent hoarseness. Routine serum calcitonin or thyroid ultrasound screening is of uncertain value for early MTC detection in this setting.

The most common adverse reactions in trials were gastrointestinal. Nausea, vomiting, diarrhea, abdominal pain, and constipation each occurred in at least 5% of treated participants and more often than with placebo. Eating smaller meals and following a clinician's titration plan can make those effects more manageable, but they are not harmless if they cause dehydration. Acute kidney injury related to volume depletion is a labeled warning. Hypoglycemia risk rises when Ozempic is combined with insulin or a sulfonylurea; those doses may need adjustment.

Stop the medicine and seek urgent evaluation for suspected pancreatitis (severe abdominal pain, sometimes with vomiting), serious hypersensitivity (anaphylaxis or angioedema), or symptoms of gallbladder disease. People with a history of diabetic retinopathy need eye follow-up. This is not a complete safety list. Read the Medication Guide and ask a clinician or pharmacist about the current prescribing information.

Why people search Ozempic for weight - and what that does not change

Ozempic is widely discussed online as a weight-loss shot because weekly GLP-1 medicines can reduce appetite and body weight in trials of other products and, as a secondary finding, in diabetes studies. That public conversation does not rewrite the FDA label. Using a diabetes medicine solely for weight management is a clinical and regulatory question for the prescriber and the patient, not something a marketing page should encourage.

If the goal is FDA-labeled chronic weight management with weekly semaglutide, that labeled product is Wegovy, which has its own doses, trials (including STEP and SELECT), and administration devices. If the goal is diabetes care, Ozempic's indications, cardiovascular data, and kidney data are the relevant frame. Switching between branded GLP-1 products is a clinician-supervised decision. There is no safe self-serve conversion chart.

Beema Health's live offering is telehealth medical weight-loss care reviewed by licensed providers. This page does not pitch any Beema product as a stand-in for Ozempic. If you want to learn how an online visit works, you can read Beema's medical weight-loss overview. A prescription is never guaranteed.

Frequently asked questions

Sources

1. [1] Ozempic (semaglutide) U.S. Prescribing Information, Novo Nordisk
2. [2] DailyMed: Ozempic (semaglutide) injection
3. [3] Marso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016.
4. [4] Perkovic V, et al. Effects of semaglutide on chronic kidney disease in type 2 diabetes (FLOW). N Engl J Med. 2024.